Overview

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Status:
Not yet recruiting

Trial end date:
2027-03-26

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to characterize the safety profile of BMS-986408 as monotherapy and in combination with nivolumab or nivolumab and ipilimumab to establish the maximum tolerated dose (MTD). The Recommended Phase 2 Dose (RP2D) that optimizes the pharmacokinetic/pharmacodynamic (PK/PD) relationship of BMS-986408 will also be determined.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Ipilimumab
Nivolumab